PROVECTUS BIOPHARMACEUTICALS EXPANDS PATENT PORTFOLIO WITH ADOPTIVE CELL TRANSFER-BASED USE OF INVESTIGATIONAL CANCER DRUG
September 18, 2018 08:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Sept. 18, 2018 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the United States Patent and Trademark Office (USPTO) has allowed the Company’s patent application for...
PROVECTUS BIOPHARMACEUTICALS ANNOUNCES ACCEPTANCE OF PV-10 POSTER PRESENTATIONS AT SMR 2018 CONGRESS
September 11, 2018 09:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Sept. 11, 2018 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from two ongoing clinical trials, single agent PV-10 and PV-10 in combination with checkpoint...
PROVECTUS BIOPHARMACEUTICALS CLINICAL TRIALS UPDATE PROVIDED AT EUROPEAN POST-CHICAGO MELANOMA/SKIN CANCER MEETING
July 10, 2018 08:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, July 10, 2018 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that a clinical trials update was provided at the 8th European Post-Chicago Melanoma/Skin Cancer Meeting,...
PROVECTUS BIOPHARMACEUTICALS COMPLETES ENROLLMENT OF PHASE 1B TRIAL OF PV-10 IN COMBINATION WITH KEYTRUDA® IN PATIENTS WITH METASTATIC MELANOMA
May 07, 2018 08:00 ET
|
Provectus Biopharmaceuticals Inc.
FOR IMMEDIATE RELEASE Data presentation planned for first half of 2019 KNOXVILLE, TN, May 07, 2018 (GLOBE NEWSWIRE) -- Provectus today announced the completion of enrollment of 24 patients...
STUDY OF T CELL MEDIATED IMMUNITY FROM COMBINATION OF PV-10 AND IMMUNE CHECKPOINT BLOCKADE IN MURINE MELANOMA MODELS PUBLISHED IN PLOS ONE
April 30, 2018 09:00 ET
|
Provectus Biopharmaceuticals Inc.
FOR IMMEDIATE RELEASE Combinations with PV-10 included + anti-CTLA-4; + anti-PD-1; + anti-PD-L1; and, + anti-PD-1 + Treg depletion Data provided basis for ongoing Phase 1b/2 study of PV-10 in...
PROVECTUS BIOPHARMACEUTICALS AND PEDIATRIC ONCOLOGY EXPERIMENTAL THERAPEUTICS INVESTIGATORS' CONSORTIUM (POETIC) ANNOUNCE ACCEPTANCE OF PV-10 POSTER PRESENTATION AT AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING
April 25, 2018 16:00 ET
|
Provectus Biopharmaceuticals Inc.
FOR IMMEDIATE RELEASE Preclinical pediatric cancer research undertaken at POETIC member institutions Alberta Children’s Hospital (Canada) and Memorial Sloan Kettering Cancer Center KNOXVILLE,...
PROVECTUS ANNOUNCES RESULTS FROM ELICITATION STUDY OF PATIENT-PERCEIVED IMPACTS FROM STAGE III AND EARLY-STAGE IV MELANOMA
October 23, 2017 08:00 ET
|
Provectus Biopharmaceuticals Inc.
– Key impacts comprised worry/concern, altered clothing choices, and limitations to physical functioning – – Study results further support the clinical significance of Provectus’ ongoing,...
PROVECTUS ANNOUNCES PRELIMINARY RESULTS FROM PHASE 1B TRIAL OF INTRALESIONAL PV-10 IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) FOR THE TREATMENT OF STAGE IV MELANOMA
October 18, 2017 09:38 ET
|
Provectus Biopharmaceuticals Inc.
– Adverse events consistent with established patterns for each drug; no unexpected toxicities observed – 50% overall objective response rate; 10% complete response; highest responses observed in...